{"id":3225,"date":"2013-05-08T06:30:00","date_gmt":"2013-05-08T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/"},"modified":"2013-05-08T06:30:00","modified_gmt":"2013-05-08T06:30:00","slug":"kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/","title":{"rendered":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ)"},"content":{"rendered":"<\/p>\n<p><span>P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma ig\u00e5r den 7 maj beslutades bl.a. f\u00f6ljande:<\/span><\/p>\n<p><span>\u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2012<\/span><\/p>\n<p><span>\u2022 Omval av styrelseledam\u00f6terna Semmy R\u00fclf, Erik von Schenck, Magnus Nilsson, Fredrik Mattsson samt nyval av Folke Nilsson och G\u00f6sta Johannesson, i enlighet med Bures f\u00f6rslag. Till styrelsens ordf\u00f6rande nyvaldes Fredrik Mattsson.<\/span><\/p>\n<p><span>\u2022 Styrelsearvode skall utg\u00e5 med totalt 470.000 kronor, varav 150.000 kronor till styrelsens ordf\u00f6rande och <\/span><span>80.000 kronor till envar av de \u00f6vriga styrelseledam\u00f6terna som inte \u00e4r anst\u00e4llda av f\u00f6retaget.<\/span><\/p>\n<p><span>\u2022 Nyval av KPMG som revisor, med auktoriserade revisorn Jan Malm som huvudansvarig revisor.<\/span><\/p>\n<p><span>\u2022 Inr\u00e4ttande av valberedning inf\u00f6r n\u00e4sta \u00e5rsst\u00e4mma, i enlighet med Bures f\u00f6rslag.<\/span><\/p>\n<p><span>\u2022 Styrelsen bemyndigades att f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma vid ett eller flera tillf\u00e4llen besluta om <\/span><span>nyemission av h\u00f6gst totalt 1.950.000 aktier motsvarande knappt 10 procent av bolagets aktiekapital.<\/span><\/p>\n<p><span>\u2022 F\u00f6reslagna principer f\u00f6r ers\u00e4ttning och andra anst\u00e4llningsvillkor f\u00f6r bolagsledningen godk\u00e4ndes.<\/span><\/p>\n<p><span>\u2022 F\u00f6reslagen emission av totalt 195.000 optionsr\u00e4tter med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier godk\u00e4ndes. Optionsr\u00e4tterna skall erbjudas anst\u00e4llda i XVIVO Perfusion-koncernen. Vid fullt utnyttjandeav optionsr\u00e4tterna kommer aktiekapitalet \u00f6ka ca 2.500 kronor motsvarande en utsp\u00e4dningen om ca 1 procent av det totala antalet aktier och r\u00f6ster. <\/span><\/p>\n<p><span>G\u00f6teborg 8 maj 2013<br \/><\/span><span>XVIVO Perfusion AB (publ)<br \/><\/span><span>Styrelsen<\/span><\/p>\n<\/p>\n<div class=\"mfn-footer\">\n<\/p>\n<p><span>Fr\u00e5gor h\u00e4nvisas till:<\/span><br \/><span>Fredrik Mattsson, styrelsens ordf\u00f6rande, telefon 08-614 00 20<\/span><br \/><span>Christoffer Rosenblad, CFO, telefon 031-788 21 59<\/span><\/p>\n<\/p>\n<p><span>Xvivo Perfusion \u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den 8 maj 2013 kl. 08:30.<\/span><\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma ig\u00e5r den 7 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2012 \u2022 Omval&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3225","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-info"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma ig\u00e5r den 7 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2012 \u2022 Omval...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\\\/\",\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-05-08T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/","og_locale":"en_US","og_type":"article","og_title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO","og_description":"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma ig\u00e5r den 7 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2012 \u2022 Omval...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/","name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-05-08T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma\u00a0i XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}